The biotech sector welcomes a new entrant, with Horien Biotech (7814) listing on the OTC market today (16th) at NT$28.47 per share. Fueled by strong June revenue and a thriving international presence in ASEAN and Europe, the stock surged to a high of NT$32.15 in the morning session, a gain of over 10%, enjoying a sweet honeymoon period.

 Horien Biotech Chairman Tsai Kuo-Tien stated that the successful OTC listing is a significant milestone for the company. Moving forward, building on its existing dental and surgical channels, the company will continue to deepen its global market penetration through top-grade medical-grade raw materials and groundbreaking high-end medical devices and drugs. With international certifications secured and innovative product lines entering their harvest period, Horien Biotech aims to create maximum value for all shareholders and the Taiwanese biotech industry through steady and rapid growth.

 Driven by continued strong demand in the US, Taiwan, and overseas markets, Haichang Biotech delivered a remarkable 209.29% revenue increase in June. In addition to its strong fundamentals, the company has also made breakthrough progress in its overseas expansion.

 Horien Biotech recently obtained three high-risk (Class 4, highest level) medical device market access licenses in Thailand, successfully entering the ASEAN high-end medical device market. Furthermore, the Philippines and Vietnam are also expected to obtain Class III medical device licenses soon, signifying that its important strategic layout in the Southeast Asian market is nearing completion.

 Horien Biotech's highly anticipated bio-ink innovative product is also planned for official export to the European market by the end of this year, extending its international footprint from Asia to Europe and America, and is expected to see significant growth in global revenue contributions.

 In the research and development of high-end innovative medical devices, Horien Biotech's independently developed "biodegradable ureteral stent" has successfully obtained a Taiwanese invention patent. Since no other company in the industry has obtained relevant medical device certifications at present, it is expected to face a pure blue ocean market worth billions of US dollars with no competition. In addition, its advanced decellularization technology has recently successfully entered the trial production stage.

Report Link:

Biomedical stocks: Horien Biotech, a newcomer in the biotech industry, saw its membership increase by over 10%, and its international expansion is flourishing.